Comparison between Aptus Pharma IPO and Fourfront IPO.
Aptus Pharma IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Fourfront IPO is a SME Bookbuilding proposed to list at BSE SME.
| Aptus Pharma IPO | Fourfront IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Interactive Financial Services Ltd. | Beeline Capital Advisors Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Market-Hub Stock Broking Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Anchor Investor | ||
| IPO Allotment URL |
The total issue size of Aptus Pharma IPO is up to ₹12.36 Cr whereas the issue size of the Fourfront IPO is up to ₹0.00 Cr. The final issue price of Aptus Pharma IPO is and of Fourfront IPO is .
| Aptus Pharma IPO | Fourfront IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹65.00 per share | |
| Issue Price (Upper) | ₹70.00 per share | |
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | |
| Fresh Issue Size | 17,66,000 shares | 65,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹12.36 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 17,66,000 shares | 65,00,000 shares |
| Issue Size Total (Amount) | up to ₹12.36 Cr | up to ₹0.00 Cr |
Aptus Pharma IPO opens on Sep 23, 2025, while Fourfront IPO opens on . The closing date of Aptus Pharma IPO and Fourfront IPO is Sep 25, 2025, and , respectively.
| Aptus Pharma IPO | Fourfront IPO | |
|---|---|---|
| Anchor Bid Date | Sep 22, 2025 | |
| Issue Open | Sep 23, 2025 | |
| Issue Close | Sep 25, 2025 | |
| Basis Of Allotment (Tentative) | Sep 26, 2025 | |
| Initiation of Refunds (Tentative) | Sep 29, 2025 | |
| Credit of Share (Tentative) | Sep 29, 2025 | |
| Listing date (Tentative) | Sep 30, 2025 | |
| Anchor Lockin End date 1 | Oct 26, 2025 | |
| Anchor Lockin End date 2 | Dec 25, 2025 |
Aptus Pharma IPO P/E ratio is 11.29, as compared to Fourfront IPO P/E ratio of .
| Aptus Pharma IPO | Fourfront IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Aptus Pharma Limited Financial Information (Restated)Aptus Pharma Limited's revenue increased by 38% and profit after tax (PAT) rose by 288% between the financial year ending with March 31, 2025 and March 31, 2024.
| Fourfront Limited Financial Information (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 72.89 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 11.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹48.02 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 44.50% | 43.88% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 45.66% | 53.51% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.49 | 0.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 44.50% | 37.64% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Aptus Pharma IPO Retail Individual Investors (RII) are offered 6,20,000 shares while in Fourfront IPO retail investors are offered 6,20,000 shares. Qualified Institutional Buyers (QIB) are offered 3,52,000 shares in Aptus Pharma IPO and in Fourfront IPO.
| Aptus Pharma IPO | Fourfront IPO | |
|---|---|---|
| Anchor Investor Reserveration | 5,28,000 shares | |
| Market Maker Reserveration | 94,000 shares | |
| QIB | 3,52,000 shares | |
| NII | 2,66,000 shares | |
| RII | 6,20,000 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 17,66,000 shares |
Aptus Pharma IPO subscribed in total, whereas Fourfront IPO subscribed .
| Aptus Pharma IPO | Fourfront IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
